Proteasome inhibitors have shown promise in cancer therapy as a single agent. We have recently observed that the proteasome inhibitor, PS-341, can sensitize neoplastic cells to TRAIL-mediated death. This sensitization occurred through the down-regulation of c-FLIP, an important mediator in the prevention of apoptosis. Surprisingly, this sensitizing activity was also shown to be independent of NF-kappaB in some tumor lines. We now wish to extend these findings to ascertain if proteasome inhibition can be used in conjunction with the killing potential of adoptive immunotherapy and the extensive cytoreductive conditioning that precedes bone marrow transplantation (BMT). To do this, several Specific Aims are proposed:
Specific Aim 1 will extend on the in vitro studies and examine the effects of PS-341 and a genetic construct for TRAIL (Fc-TRAIL) or a recently obtained agonist TRAIL receptor antibody (anti-DR5) on advanced tumor-bearing mice. The mechanism underlying the anti-tumor effects will also be dissected using TRAIL KO mice.
Specific Aim 2 will assess the effects of PS-341, with or without Fc-TRAIL or anti-DR5, in a minimal residual disease model in which the tumor-bearing mice receive a bone marrow transplant (BMT). Both syngeneic and allogeneic BMT will be used and effects on immune and myeloid reconstitution as well as tumor relapse will be assessed. In allogeneic BMT models, effects on graft-versus-host disease (GVHD) will be ascertained. Finally, in Specific Aim 3, effects of PS-341 as a means to sensitize tumor cells to T and NK cell killing will be determined using both in vitro and in vivo assays. This will culminate with combining the data attained from the previous specific aims and assessing the effects of PS-341 with NK cells and anti-DR5 as an adoptive immunotherapy regimen in resting tumor-bearing mice and in tumor-bearing mice after BMT. These results will allow for the assessment of the efficacy of proteasome inhibition with PS-341 in conjunction with immunotherapy using a variety of tumor types and in preclinically-relevant models.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA102282-05
Application #
7355533
Study Section
Special Emphasis Panel (ZRG1-DT (02))
Program Officer
Mccarthy, Susan A
Project Start
2004-04-15
Project End
2009-06-30
Budget Start
2008-03-01
Budget End
2009-06-30
Support Year
5
Fiscal Year
2008
Total Cost
$253,662
Indirect Cost
Name
University of Nevada Reno
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
146515460
City
Reno
State
NV
Country
United States
Zip Code
89557
Pai, Chien-Chun Steven; Khuat, Lam T; Chen, Mingyi et al. (2017) Therapeutic Effects of a NEDD8-Activating Enzyme Inhibitor, Pevonedistat, on Sclerodermatous Graft-versus-Host Disease in Mice. Biol Blood Marrow Transplant 23:30-37
Zamora, Anthony E; Grossenbacher, Steven K; Aguilar, Ethan G et al. (2015) Models to Study NK Cell Biology and Possible Clinical Application. Curr Protoc Immunol 110:14.37.1-14
Quintás-Cardama, Alfonso; Zhang, Nianxiang; Qiu, Yi Hua et al. (2015) Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 15:115-127.e15
Pai, Chien-Chun Steven; Hsiao, Hui-Hua; Sun, Kai et al. (2014) Therapeutic benefit of bortezomib on acute graft-versus-host disease is tissue specific and is associated with interleukin-6 levels. Biol Blood Marrow Transplant 20:1899-904
Pai, Chien-Chun Steven; Chen, Mingyi; Mirsoian, Annie et al. (2014) Treatment of chronic graft-versus-host disease with bortezomib. Blood 124:1677-88
Ames, Erik; Harouna, Salif; Meyer, Colin et al. (2012) The triterpenoid CDDO-Me promotes hematopoietic progenitor expansion and myelopoiesis in mice. Biol Blood Marrow Transplant 18:396-405
Sun, Kai; Hsiao, Hui-Hua; Li, Minghui et al. (2012) IFN-? receptor-deficient donor T cells mediate protection from graft-versus-host disease and preserve graft-versus-tumor responses after allogeneic bone marrow transplantation. J Immunol 189:2033-42
Bouchlaka, Myriam N; Redelman, Doug; Murphy, William J (2010) Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects. Immunotherapy 2:399-418
Koreth, John; Alyea, Edwin P; Murphy, William J et al. (2009) Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review. Biol Blood Marrow Transplant 15:1502-12
Ames, E; Hallett, W H D; Murphy, W J (2009) Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition. Clin Exp Immunol 155:504-13

Showing the most recent 10 out of 23 publications